10x Genomics Strengthens Executive Leadership Team with Appointment of John Pouk as Chief Commercial Officer

September 21, 2016

Pouk Brings Accomplished Leadership To Head Commercial Activities

PLEASANTON, Calif. – September 21, 2016 – 10x Genomics, a company focused on improving and broadening the application of genomic information, today announced the appointment of John Pouk as chief commercial officer of the company. In this role, Mr. Pouk will continue to advance 10x Genomics' commercialization and market development efforts by leading global sales and customer support, and securing new distribution agreements in key regions for market growth.

"10x Genomics is pleased to have John join our executive team," said Serge Saxonov, co-founder and chief executive officer of 10x Genomics. "His extensive knowledge and proven leadership in developing commercial teams and distributor networks are unsurpassed. John has shown himself to be a pivotal leader, and we are confident he will maximize the commercial success of 10x in our ever expanding global markets."

Mr. Pouk brings more than 30 years of leadership, operational and commercial experience in the life sciences and diagnostics industry to 10x Genomics, working nearly 20 of those years in global sales. He joins 10x Genomics from Agilent Technologies, where he served in various executive roles including senior vice president Global Sales and International Operations and senior vice president and general manager Worldwide Life Science Sales. Mr. Pouk served as senior vice president of Global Sales and International Operations at Stratagene from 1996 until 2007, when the company was acquired by Agilent Technologies.

He also served in various capacities within the life sciences and medical divisions of Fisher Scientific Company, including vice president and general manager of the western region from 1989 to1996. Mr. Pouk holds a B.A. degree in Biology and a graduate degree in Medical Technology from Augustana College in Illinois.

"I am excited to join a company with such innovative and industry-changing products. In a very short time, 10x Genomics has dramatically advanced their Linked-Reads and single cell expression analysis technologies," said Mr. Pouk. "The opportunities for commercial growth that exist for the 10x Chromium System and underlying GemCode Technology are far-reaching, and I am eager to accelerate adoption of these products within the next generation sequencing (NGS) and Single Cell analysis markets."

About 10x Genomics

10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCode Technology within the Chromium System, researchers can now, for the first time, find new structural variants, haplotypes, and other valuable genomic information with comprehensive workflows for Single Cell, Genome and Exome applications that incorporate their pre-existing sequencing technologies.

Media Contact

Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com

Investor Contact

Matt Clawson
Pure Communications, Inc.
(949) 370-8500
matt@purecommunicationsinc.com